8-K: Novartis to Acquire Tourmaline Bio for $1.4 Billion

Novartis AG will acquire Tourmaline Bio, Inc. for $48.00 per share in cash, totaling approximately $1.4 billion, representing a significant premium for shareholders.

Summary

• Novartis AG, through its indirect wholly owned subsidiary Torino Merger Sub Inc., has entered into an Agreement and Plan of Merger to acquire Tourmaline Bio, Inc.
• The acquisition price is $48.00 per share in cash, without interest, for all outstanding shares of Tourmaline Bio common stock.
• The total equity value of the transaction is approximately $1.4 billion.
• This offer represents a premium of 59% to Tourmaline's closing stock price on September 8, 2025, and 127% to its 60-day volume-weighted average stock price as of the same date.
• The Boards of Directors of both Tourmaline Bio and Novartis AG have unanimously approved the transaction.
• The acquisition is driven by the potential of Tourmaline's lead asset, pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody, for the treatment of cardiovascular diseases.
• The transaction is expected to be completed in the fourth quarter of 2025, subject to customary closing conditions, including the tender of a majority of outstanding shares and receipt of regulatory approvals.

Sentiment

Score: 9

Explanation: The acquisition by Novartis at a significant premium represents a highly positive outcome for Tourmaline Bio shareholders and validates the potential of its lead asset, pacibekitug. The unanimous board approval and strategic alignment with Novartis's focus on cardiovascular diseases further enhance the positive sentiment, despite standard transaction risks.

Positives

• Shareholders will receive a substantial premium of 59% over the last closing price and 127% over the 60-day volume-weighted average stock price.
• The transaction has received unanimous approval from the Boards of Directors of both Tourmaline Bio and Novartis AG, indicating strong confidence in the deal.
• Novartis's acquisition will accelerate the development of pacibekitug, a potential 'best-in-class' anti-IL-6 monoclonal antibody, addressing a critical unmet medical need in cardiovascular inflammation.
• Novartis's deep roots and commitment to innovation in cardiovascular, renal, and metabolic diseases provide an ideal partnership for advancing pacibekitug.

Risks

• Uncertainties exist regarding the timing of the tender offer and the overall transaction completion.
• There are uncertainties as to how many of Tourmaline's stockholders will tender their shares in the offer.
• The possibility of competing offers or alternative acquisition proposals being made could disrupt the current agreement.
• Various closing conditions for the transaction may not be satisfied or waived, including the risk that a governmental entity may prohibit, delay, or refuse to grant approval, or grant approval subject to adverse conditions.
• The difficulty of predicting the timing or outcome of regulatory approvals or actions, including under the HSR Act and other Antitrust and FDI Laws.
• The occurrence of any event, change, or circumstance that could give rise to the termination of the Merger Agreement.
• Risks related to the parties' ability to realize the anticipated benefits of the proposed transaction, including potential difficulties, higher costs, or longer timelines for integration.
• The transaction could negatively affect relationships with employees, suppliers, manufacturers, other business partners, or governmental entities.
• Significant transaction costs are expected.
• There is a risk of unknown or inestimable liabilities.
• The risk of litigation and/or regulatory actions related to the proposed transaction.
• Novartis's ability to fund the proposed transaction is a factor.
• Uncertainties inherent in the costly and time-consuming therapeutic product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials.
• Global economic, financial, and healthcare system disruptions could negatively impact the parties' business operations and financial results.
• The sufficiency of the parties' cash flows and capital resources, and the uncertainty of future tax, accounting, and other provisions and estimates.

Future Outlook

The transaction is expected to be completed in the fourth quarter of 2025, contingent on customary closing conditions and regulatory approvals. Novartis plans to integrate pacibekitug into its portfolio and accelerate its development, aiming to address residual inflammatory risk in atherosclerotic cardiovascular disease (ASCVD) and diversify its cardiovascular care efforts.

Management Comments

• Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline, stated: 'Our mission at Tourmaline has been to establish new standards of care in areas of high unmet medical need, and today's transaction announcement both underscores our commitment to that focus and also delivers compelling shareholder value.'
• Dr. Kulkarni also expressed: 'We are thrilled that Novartis, a company with deep roots and a commitment to innovation in the cardiovascular, renal, and metabolic disease space, will continue to advance this mission. Novartis shares our conviction in the critical, but largely unaddressed, role of inflammation in driving cardiovascular diseases and will be an ideal partner to accelerate the development of pacibekitug.'
• Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, commented: 'With no widely adopted anti-inflammatory therapies currently available for cardiovascular risk reduction, pacibekitug represents a potential breakthrough in addressing residual inflammatory risk in ASCVD with a differentiated mechanism of action targeting IL-6.'
• Dr. Aradhye further added: 'Inflammation is a major driver of cardiovascular disease, and the team at Tourmaline has made significant progress with this asset. We are excited to bring pacibekitug into the Novartis portfolio and collaborate with the Tourmaline team to advance its development as we diversify our efforts in cardiovascular care.'

Industry Context

This acquisition highlights a strategic move by Novartis to strengthen its position in cardiovascular care by targeting inflammatory pathways, an area with significant unmet medical need. The industry is increasingly recognizing the critical role of inflammation in driving cardiovascular diseases, and pacibekitug, as an anti-IL-6 monoclonal antibody, represents a differentiated approach in a market currently lacking widely adopted anti-inflammatory therapies for risk reduction. This transaction could set a precedent for further consolidation or strategic investments in companies developing novel anti-inflammatory treatments for chronic diseases.

Comparison to Industry Standards

• The acquisition price of $48.00 per share represents a substantial premium of 59% to Tourmaline's closing stock price on September 8, 2025, and 127% to its 60-day volume-weighted average stock price, indicating a highly favorable valuation for Tourmaline's assets and pipeline compared to its recent market performance.
• The filing does not provide specific comparable companies, projects, or acquisition multiples from other industry transactions for a direct benchmark comparison.

Corporate Governance

Legal Proceedings

• Risk of litigation and/or regulatory actions related to the proposed transaction.
• The Company will provide prompt notice to Parent of all Transaction Litigation and consult on defense, settlement, or prosecution.
• The Company may not compromise or settle any Transaction Litigation without Parent's prior written consent.

Stakeholder Impact

• Shareholders: Will receive $48.00 per share in cash, representing a significant premium over recent trading prices, providing a clear and favorable exit.
• Employees: Continuing employees will receive at least the same base salary, target annual cash incentive compensation opportunities, and substantially comparable retirement and health and welfare benefits for at least one year following the Effective Time. Service credit will be recognized for Parent Plans.
• Customers/Patients: The development of pacibekitug, a potential treatment for cardiovascular diseases, is expected to be accelerated under Novartis, potentially benefiting patients with unmet medical needs.
• Suppliers/Business Partners: Relationships with suppliers, manufacturers, and other business partners may be affected by the transaction, as noted in the risk factors.

Next Steps

• Purchaser will commence a cash tender offer no later than September 29, 2025, to acquire all outstanding shares of Tourmaline Bio.
• The closing of the tender offer is subject to conditions, including the tender of shares representing at least a majority of the total outstanding shares and receipt of regulatory approvals.
• Following the tender offer, a merger will be effected where Purchaser merges into Tourmaline Bio, with Tourmaline Bio continuing as the surviving corporation and an indirect wholly owned subsidiary of Novartis.
• Tourmaline Bio will continue to operate as a separate and independent company until the transaction is completed.
• Novartis will advance the development of pacibekitug.
• After the Effective Time, Tourmaline Bio common stock will be delisted from Nasdaq and deregistered under the Exchange Act.

Key Dates

Recommendation

The acquisition by Novartis at a 59% premium to the last closing price and 127% to the 60-day VWAP provides a clear and compelling exit for Tourmaline Bio shareholders. For existing shareholders, tendering shares at $48.00 cash per share is highly recommended. For investors considering an arbitrage play, if the stock trades below the offer price, it presents a strong buy opportunity, assuming the deal closes as expected in Q4 2025.

Keywords

Tourmaline Bio, Novartis, Acquisition, Merger, Tender Offer, Pacibekitug, IL-6 monoclonal antibody, Cardiovascular Disease, Inflammatory Diseases, Biotechnology, Pharmaceuticals, SEC Filing, TRML